Effects of platelet and inflammatory system activation on outcomes in diabetic patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention

Kardiologia Polska

Volumn 69, Issue 6, 2011, Pages 531-537

  Kuliczkowski, Wiktor ^a   Greif, Małgorzata ^a   Ga̧sior, Mariusz ^a   Kaczmarski, Jacek ^a   Pres, Damian ^a   Poloński, Lech ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Acute coronary syndrome; Diabetes; Primary percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; C REACTIVE PROTEIN; CLOPIDOGREL; COLLAGEN; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENT; DIABETIC PATIENT; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INFLAMMATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; RECURRENT DISEASE; RESTENOSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS;

EID: 79959323846     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Boyden TF, Nallamothu BK, Moscucci M et al. Meta-analysis of randomized trials of drug-eluting stents versus bare metal stents in patients with diabetes mellitus. Am J Cardiol, 2007; 99: 1399-1402. (Pubitemid 46686640)
2. Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. JAMA, 2005; 293: 1501-1508. (Pubitemid 40393296)
3. Tanguay JF, Geoffroy P, Sirois MG et al. Prevention of in-stent restenosis via reduction of thrombo-inflammatory reactions with recombinant P-selectin glycoprotein ligand-1. Thromb Haemost, 2004; 91: 1186-1193. (Pubitemid 38821276)
4. Wang K, Zhou X, Zhou Z et al. Platelet, not endothelial, P-selectin is required for neointimal formation after vascular injury. Arterioscler Thromb Vasc Biol, 2005; 25: 1584-1589. (Pubitemid 41098925)
5. Schober A, Manka D, von Hundelshausen P et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation, 2002; 106: 1523-1529.
6. Fox KA, Dabbous OH, Goldberg RJ et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ, 2006; 333: 1091-1094.
7. Lau KW, Ding ZP, Johan A et al. Midterm angiographic outcome of single-vessel intracoronary stent placement in diabetic versus nondiabetic patients: a matched comparative study. Am Heart J, 1998; 136: 150-155. (Pubitemid 28317880)
8. Kuliczkowski W, Witkowski A, Polonski L et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J, 2009; 30: 426-435.
9. Hemetsberger R, Farhan S, Strehblow C et al. Association between the efficacy of dual antiplatelet therapy and the development of in-stent neointimal hyperplasia in porcine coronary arteries. Coron Artery Dis, 2008; 19: 635-643.
10. Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost, 2007; 5 (suppl. 1): 230-237. (Pubitemid 46958838)
11. Can MM, Tanboga IH, Turkyilmaz E et al. The risk of false results in the assessment of platelet function in the absence of antiplatelet medication: Comparision of the PFA-100, multiplate electrical impedance aggregometry and verify now assays. Thromb Res, 2010; 125: e132-e137.
12. Sibbing D, Morath T, Braun S et al. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost, 2010; 103: 151-159.
13. Snoep JD, Hovens MM, Eikenboom JC et al. Clopidogrel non -responsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J, 2007; 154: 221-231. (Pubitemid 47069129)
14. Snoep JD, Hovens MM, Eikenboom JC et al. Association of laboratory- defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med, 2007; 167: 1593-1599. (Pubitemid 47280339)
15. Frelinger AL, III, Li Y, Linden MD et al. Association of cyclooxygenase- 1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation, 2009; 120: 2586-2596.
16. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. Am Heart J, 2009; 158: 327-334.
17. Becker RC, Moliterno DJ, Jennings LK et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet, 2009; 373: 919-928.
18. Buffon A, Liuzzo G, Biasucci LM et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol, 1999; 34: 1512-1521. (Pubitemid 29528666)
19. Rittersma SZ, de Winter RJ, Koch KT et al. Preprocedural C-reactive protein is not associated with angiographic restenosis or target lesion revascularization after coronary artery stent placement. Clin Chem, 2004; 50: 1589-1596. (Pubitemid 39121227)